Cargando…
20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
BACKGROUND: Approximately 5–8% of melanoma patients will develop in-transit metastases (IT-mets). Tumor necrosis factor-α (TNF) and melphalan-based isolated limb perfusion (TM-ILP) is an attractive treatment modality in melanoma patients with multiple IT-mets. This study reports on a 20 years experi...
Autores principales: | Deroose, Jan P., Eggermont, Alexander M. M., van Geel, Albertus N., de Wilt, Johannes H. W., Burger, Jacobus W. A., Verhoef, Cornelis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264869/ https://www.ncbi.nlm.nih.gov/pubmed/21879272 http://dx.doi.org/10.1245/s10434-011-2030-7 |
Ejemplares similares
-
Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
por: Prens, Sebastiaan P., et al.
Publicado: (2011) -
Therapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection
por: van der Ploeg, A. P. T., et al.
Publicado: (2011) -
Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008) -
Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma
por: van Akkooi, A. C. J., et al.
Publicado: (2008) -
Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity Sarcoma
por: Verhoef, Cornelis, et al.
Publicado: (2007)